title: L-lysine effectively blocks renal uptake of 125I- or 99mTc-labeled anti-Tac disulfide-stabilized Fv fragment.
abstract: In this study, we investigated the ability of L-lysine to block renal uptake of 125I- or 99mTc- labeled Fv fragments. Anti-Tac disulfide-stabilized Fv fragment (dsFv) was derived from a murine monoclonal antibody that recognizes the alpha subunit of the interleukin-2 receptor (IL-2R alpha). The 125I- or 99mTc-labeled dsFv was injected i.v. into non-tumor-bearing nude mice or into nude mice bearing SP2/Tac (IL-2R alpha positive) and SP2/0 (IL-2R alpha negative) tumor. We then evaluated the pharmacokinetics of L-[3H]lysine and the effect of L-lysine dose, timing of administration, and route of delivery on catabolism and biodistribution of i.v. dsFv. Peak renal uptake of i.v. or i.p. injected L-[3H]lysine occurred within 5 and 15 min, respectively. The kidney uptake of L-lysine exhibited a dose-response effect. When L-lysine was coinfused or injected shortly before dsFv, renal uptake of dsFv was blocked to < 5% of the control, but longer intervals were less effective. Aminosyn II and Travasol 10% (parenteral amino acid solutions) also blocked renal uptake of radiolabeled dsFv. Administration of L-lysine did not alter the blood kinetics and slightly increased the tumor uptake of dsFv, but it did prevent catabolism in the kidney and resulted in lower amounts of catabolites in the serum and urine. In conclusion, we have shown that a blocking dose of lysine, injected with or immediately before the injection of radiolabeled dsFv, is most effective in blocking the renal uptake of dsFv. This is consistent with the rapid uptake of L-[3H]lysine by the kidney and is further substantiated by the relative ineffectiveness of lysine injected immediately after the radiolabeled dsFv injection.
authors.affiliation: Department of Nuclear Medicine, National Cancer Institute, National Institutes of Health, Bethesda, Maryland 20892-1180, USA.
authors.forename: H
authors.initials: H
authors.lastname: Kobayashi
authors.forename: T M
authors.initials: TM
authors.lastname: Yoo
authors.forename: I S
authors.initials: IS
authors.lastname: Kim
authors.forename: M K
authors.initials: MK
authors.lastname: Kim
authors.forename: N
authors.initials: N
authors.lastname: Le
authors.forename: K O
authors.initials: KO
authors.lastname: Webber
authors.forename: I
authors.initials: I
authors.lastname: Pastan
authors.forename: C H
authors.initials: CH
authors.lastname: Paik
authors.forename: W C
authors.initials: WC
authors.lastname: Eckelman
authors.forename: J A
authors.initials: JA
authors.lastname: Carrasquillo
mesh_terms: D000818:Animals; D000911:Antibodies, Monoclonal / Q000378:metabolism*; D004305:Dose-Response Relationship, Drug; D005260:Female; D005919:Glomerular Filtration Rate / Q000187:drug effects; D007128:Immunoglobulin Fragments / Q000378:metabolism*; D007457:Iodine Radioisotopes; D007668:Kidney / Q000378:metabolism*; D008239:Lysine / Q000493:pharmacokinetics / Q000494:pharmacology*; D051379:Mice; D008819:Mice, Nude; D009374:Neoplasms, Experimental / Q000378:metabolism; D015375:Receptors, Interleukin-2 / Q000276:immunology*; D013667:Technetium; D014018:Tissue Distribution
chemical_list: D000911:Antibodies, Monoclonal; D007128:Immunoglobulin Fragments; D007457:Iodine Radioisotopes; D015375:Receptors, Interleukin-2; C055966:immunoglobulin Fv; D013667:Technetium; D008239:Lysine